Table 1 Case description and assays performed.
Case no. | Diagnosis | HRAS/BRAF status | Molecular assays | Immunohistochemistry | |||
|---|---|---|---|---|---|---|---|
RNA-seq | qPCR | EMT markers* | pERK1/2** | ODAM** | |||
1 | CAA | HRAS p.Q61R | Yes | Yes | < 20% | ND | ND |
2 | CAA | HRAS p.Q61R | Yes | Yes | 50% | ++ | ND |
3 | CAA | HRAS p.Q61R | No | Yes | ND | ND | ND |
4 | CAA | HRAS p.Q61R | Yes | Yes | 90% | ND | +++ |
5 | CAA | HRAS p.Q61R | Yes | Yes | ND | ND | ND |
6 | CAA | HRAS p.Q61R | Yes | Yes | 50% | ND | ND |
7 | CAA | HRAS p.Q61R | Yes | Yes | ND | ND | ND |
8 | CAA | HRAS p.Q61R | Yes | Yes | ND | ++ | ND |
9 | CAA | HRAS p.Q61R | No | Yes | ND | ND | ND |
10 | CAA | HRAS p.Q61R | No | Yes | ND | ND | ND |
11 | CAA | HRAS p.Q61R | Yes | Yes | < 20% | ND | ND |
12 | CAA | HRAS p.Q61R | Yes | Yes | 75% | ++ | ND |
13 | CAA | HRAS p.Q61R | Yes | Yes | ND | +++ | ND |
14 | CAA | HRAS p.Q61R | Yes | Yes | 50% | ND | +++ |
15 | CAA | HRAS p.Q61R | No | Yes | ND | +++ | ND |
16 | CAA | WT | Yes | Yes | 90% | ND | ND |
17 | OSCC | WT | No | Yes | ND | ND | ND |
18 | OSCC | BRAF p.V600E | Yes | Yes | ND | ++ | ND |
19 | OSCC | WT | Yes | Yes | ND | ND | ND |
20 | OSCC | WT | Yes | Yes | ND | + | ND |
21 | OSCC | WT | Yes | Yes | ND | ND | ND |
22 | OSCC | HRAS p.Q61L | Yes | Yes | ND | + | ND |
23 | OSCC | WT | Yes | Yes | ND | +++ | ND |
24 | OSCC | BRAF p.V600E | Yes | Yes | ND | ND | ND |
25 | HGIN | WT | Yes | Yes | ND | ND | ND |
26 | HGIN | WT | Yes | Yes | ND | ND | ND |
27 | HGIN | WT | Yes | Yes | ND | ND | ND |
28 | HGIN | WT | Yes | Yes | ND | ND | ND |
29 | CAA | ND | No | No | ND | ++ | ND |
30 | CAA | ND | No | No | ND | +++ | ND |
31 | CAA | ND | No | No | ND | +++ | ND |
32 | CAA | ND | No | No | ND | ++ | ND |
33 | OSCC | ND | No | No | ND | +++ | ND |
34 | OSCC | ND | No | No | ND | +++ | ND |
35 | OSCC | ND | No | No | ND | +++ | ND |
36 | OSCC | WT | Yes | No | ND | ND | ND |
37 | HGIN | WT | Yes | No | ND | ND | ND |
